Fine-needle Aspiration Washout Precipitation Specimens: An Acceptable Supplement to Genetic Mutation Detection of Thyroid Nodules

Yongmei Cui, MD,*, Xiangqi Huang, MD,*, Jinrui Guo, MS, Nana Zhang, MD, Jing Liang, MD, Yiwang Zhang, MD, Yueting Liao, MD, and Dan He, MD

Abstract
Objectives: Thyroid nodules are common in adults, but only some of them are malignant. Ultrasound-guided fine-needle aspiration (FNA) is widely applied as a reliable and minimally invasive technique for evaluating thyroid nodules. However, the scarcity of FNA biopsy specimens poses a challenge to molecular diagnosis. This study aimed to evaluate the feasibility of FNA washout precipitation specimens as an effective supplement to the thyroid genetic test.

Methods: A total of 115 patients with thyroid nodules were enrolled in our study. The BRAF V600E mutation status was detected in all FNA washout precipitation specimens and biopsy formalin-fixed paraffin-embedded (FFPE) specimens using an amplification refractory mutation system PCR (ARMS-PCR). All patients underwent cytological diagnoses; 79 patients also underwent surgery for histopathological analysis.

Results: All the 115 samples were successfully analyzed using both FNA washout precipitation and biopsy FFPE specimens. The results showed that the BRAF V600E status detected in 96 FNA washout precipitation specimens were consistent with that in FNA biopsy FFPE specimens, including 41 BRAF V600E positive and 55 BRAF V600E negative, achieving a concordance rate of 84.4% (kappa = 0.689). Furthermore, the BRAF V600E mutation status using FNA washout precipitation specimens provided a 100.0% positive predictive value for diagnosing papillary thyroid carcinoma in patients with The Bethesda system for reporting thyroid cytopathology (TBSRTC) V. Besides, the BRAF V600E mutation status was positive in 90.9% (10/11) FNA washout precipitation specimens from patients with capsule invasion, achieving a higher overall sensitivity of 100.0%, compared with 57.1% of FNA washout precipitation specimens from patients without capsule invasion.

Conclusion: These results suggested that FNA washout precipitation specimens might be a valuable supplementary sample type for detecting the BRAF V600E mutation in patients with thyroid nodules, especially with thyroid capsule invasion.

Keywords
amplification refractory mutation system, BRAF, fine-needle aspiration (FNA), thyroid nodule, washout specimen

Introduction

Thyroid nodules are widespread in the general population, with a prevalence of approximately 70.0% in an adult undergoing ultrasonography, but only 5.0%–15.0% of nodules are malignant.[1–3] Therefore, it is important to differentiate benign from malignant nodules so as to prevent undertreatment or overtreatment. Ultrasound-guided fine-needle aspiration (FNA) biopsy is a reliable method with good sensitivity and specificity for a definitive benign or malignant diagnosis of thyroid nodules.[4,5] However, the limitations of FNA include nondiagnostic modality, indeterminate cytology, and false-
Biopsy Formalin-Fixed Paraffin-Embedded Specimens
Thyroid FNA biopsy samples were centrifuged at 3500 rpm for 10 min in a 15-mL centrifuge tube with sample preservation solution. After the supernatant was discarded, 1 mL of buffer solution was added to clean the sediment. After centrifugation at 3500 rpm for 10 min again, the precipitate was wrapped in rice paper and put into an embedding box, followed by dehydration using a Leica dehydrator. The next day, the embedding box was taken out, and wax blocks were prepared.

FNA Washout Precipitation Specimens
After collecting FNA cytology samples, each needle was rinsed with 1.0 mL of saline (0.9% w/v NaCl). The wash solution from all needles was centrifuged at 2000rpm for 10 min to collect the residue. All the samples were stored at 4 °C until use, and the maximum storage time of all samples was less than 24 h.

DNA Extraction
DNA was extracted from the formalin-fixed paraffin-embedded (FFPE) samples and FNA washout precipitation specimens using an AmoyDx FFPE DNA Extraction Kit (Amoy Diagnostics Co., Ltd, Xiamen, China) following the manufacturer’s protocols. A Nanodrop spectrophotometer (Thermo-Fisher Scientific, USA) was used to assess the concentration and purity of extracted DNA.

Mutation Screening of BRAF V600E
BRAF V600E mutations were tested using an AmoyDx BRAF Mutations Detection Kit (Amoy Diagnostics Co., Ltd, Xiamen, China) following the principle of the amplification refractory mutation system. Briefly, ARMS-PCR was carried out on a 7500 Real-Time PCR System (Applied Biosystems) following the manufacturer’s protocol. The cycling conditions were as follows: 1 cycle of initial denaturation for 5 min at 95 °C (1 cycle), followed by 15 cycles at 95 °C for 25 s, 64 °C for 20 s, and 72 °C for 20 s, with a final step of annealing and elongation of 31 cycles at 93 °C for 25 s, 60 °C for 35 s, and 72 °C for 20 s. Threshold cycle (CT) values were recorded when the mixtures were amplified to a specific fluorescent level. All results were confirmed according to the criterion suggested by the manufacturer.

Statistical Analysis
The analysis was performed using SPSS 23.0 (IBM Inc., IL, USA). McNemar–Bowker test and kappa (κ) statistics were used to analyze and indicate the concordance of results generated by washout precipitation and FFPE samples. The relationship between gene mutations and clinicopathological characteristics was analyzed using the χ² test or Fisher’s exact test. The two-sided significance level was set at P<0.05.
Results

Case Date and Clinical Features

Ultrasound-guided FNA was performed in 115 patients with thyroid nodules. The clinical characteristics of 115 patients are shown in Table 1. The relationship between clinicopathological characteristics and BRAF V600E mutation status in FNA FFPE biopsy samples was analyzed. The result showed that a higher mutation frequency of BRAF V600E was observed in patients with a higher TIADRS score and a TBSRTC score. No statistically significant differences were observed in sex, age, nodal diameter, and nodule number.

Concordance of BRAF V600E detected using FNA washout precipitation and biopsy FFPE specimens

A total of 115 samples were successfully analyzed using both FNA washout precipitation and biopsy FFPE specimens. The results of 96 patients were consistent between FNA washout precipitation and biopsy FFPE specimens, with 41 BRAF V600E positive and 55 BRAF V600E negative, achieving a concordance rate of 84.4% [95% confidence interval (CI): 0.762 to 0.902]. Further, 19 samples had inconsistent results, including 18 FFPE-positive/washout-negative specimens and 1 FFPE-negative/washout-positive specimen. As shown in Table 2, compared with FNA biopsy FFPE specimens, BRAF V600E alterations detected in FNA washout precipitation specimens showed a substantial degree of concordance (kappa = 0.671, 95% CI: 0.706-0.951) with 98.2% specificity (95% CI: 0.892-0.999) and 97.96% PPV (95% CI: 0.859-0.999).

Comparison of BRAF V600E detected using biopsy FFPE and FNA washout precipitation specimens among patients with PTC

A total of 79 patients diagnosed as PTC by histopathology (including 2 TBSRTC II, 47 TBSRTC V, and 30 TBSRTC VI) were analyzed. The results showed that 74.7% (59 / 79) patients with PTC carried BRAF V600E mutation in the FNA biopsy FFPE specimens, while the rate detected in the FNA washout precipitation specimens was 54.4% (43 / 79). In addition, the results of BRAF V600E detected with FNA washout precipitation specimens were used to diagnose PTC in patients classified as TBSRTC V, and a 100.0% PPV was obtained (Figure 1). Thyroid capsule invasion increases recurrence rates and is one of the poor prognostic factors. Therefore, the BRAF V600E mutation status in patients with PTC was subjected to the stratification analysis of capsule invasion. As shown in Table 3, the BRAF V600E mutation status was shown to be positive in 90.9% (10/11) of patients with capsule invasion using FNA washout precipitation specimens (achieving a higher overall sensitivity of 100.0%) than that in 57.1% of patients without capsule invasion using FNA washout precipitation specimens.

Relationship between clinical characteristics and BRAF V600E status in patients with PTC

Furthermore, the relationship between BRAF V600E mutation status and clinical characteristics, including sex, age, lesion numbers, tumor size, capsule invasion, and lymph metastasis of patients with PTC, was analyzed. The results showed that the BRAF V600E mutation was significantly associated with tumor size (P = 0.030) and was more common in patients with a tumor diameter ≥10 mm (Table 4).

Discussion

The TBSRTC system (2017 version) is generally used as the diagnostic standard for thyroid cytopathology in China and
the preferred method for benign and malignant screening of thyroid nodules.\textsuperscript{15,16} However, TBSRTC III–V, which are uncertain diagnoses, pose significant clinical challenges because benign and malignant diagnoses directly determine the subsequent treatment. The *BRAF* V600E mutation is commonly found in PTC; in China, its mutation rate is up to 69.0%–85.3% in patients with PTC.\textsuperscript{17–19} The *BRAF* V600E mutation is proposed as a diagnostic adjunctive tool in the differential diagnosis of indeterminate cytological findings and prognostic evaluation of thyroid nodules, which guide the optimal management.\textsuperscript{20,21} Moreover, *BRAF/RAS* mutations and RET/PTC rearrangement are also used for the diagnosis of thyroid nodules.\textsuperscript{4,8}

With the growing number of molecular biomarkers needed for the clinical management of patients with thyroid cancer, the judicious use of limited-volume specimens is critically needed. Thyroid FNA washout precipitation specimens have become a promising alternative for molecular analysis because they are of a less invasive nature and easy to perform. Giulia et al. evaluated the practical application of *BRAF* V600E mutation analysis in FNA washout precipitation specimens from thyroid nodule FNA; 20 nodules were positive for *BRAF* V600E, while 869 nodules were wild type.\textsuperscript{22} However, direct head-to-head comparison studies for detecting *BRAF* V600E between FNA washout precipitation and biopsy FFPE specimens are scarce.

In this study, 115 samples were successfully analyzed using both FNA washout precipitation and biopsy FFPE specimens. The results showed that the *BRAF* V600E status detected in 96 FNA washout precipitation specimens was consistent with that detected in FNA biopsy FFPE specimens, including 41 *BRAF* V600E positive and 55 *BRAF* V600E negative, achieving a concordance rate of 84.4% (kappa = 0.671). The low proportion of tumor cells in washout specimen may contribute to the inconsistency of the 19 samples, including 18 FFPE (+) / washout (-) specimens and 1 FFPE (-) / washout (+) specimen. It is quite possible that the proportion of tumor cells in washout specimen is too low to get adequate positive *BRAF* V600E signal. In clinical practice, it is generally recommended that the content of tumor cells in the samples

**Table 3.** Comparison of *BRAF* mutation detection in FNA biopsy FFPE or washout precipitation specimens from patients with PTC with or without capsule invasion

|                      | Without capsule invasion | With capsule invasion |
|----------------------|--------------------------|-----------------------|
|                      | (n = 27)                 | (n = 11)              |
| Washout( +)          | 12                       | 10                    |
| FFPE( + )            | 0                        | 0                     |
| FFPE( - )            |                          |                       |
| P value              | *Kappa* = 0.372          | *Kappa* = 1.000       |
|                      | *P* = 0.002              | *P* = 0.500           |
| Sensitivity% (95% CI)| 0.571 (0.344-0.774)      | 1.000 (0.655-1.000)   |
| Specificity% (95% CI)| 1.000 (0.517-1.000)      | 1.000 (0.555-1.000)   |
| PPV% (95% CI)        | 1.000 (0.699-1.000)      | 1.000 (0.655-1.000)   |
| NPV% (95% CI)        | 0.400 (0.175-0.671)      | 1.000 (0.555-1.000)   |
| Concordance rate (95% CI) | 0.667 (0.460-0.828) | 1.000 (0.679-1.000) |

\*without capsule invasion; \*with capsule invasion
used for molecular detection should be above 20%. Unfortunately, due to the lack of sufficient FNA washout precipitation, we were unable to assess the percentage of tumor cells. Next, the comparative studies of proportion of tumor cells between different specimens will be considered in the future. For the FNA washout precipitation specimen with \textit{BRAF} V600E positive, while the FNA biopsy FFPE specimen was negative. The histopathological diagnosis was papillary carcinoma. Therefore, it was highly suspected that the FNA washout precipitation specimen that detected the \textit{BRAF} mutation originated from a malignant thyroid nodule.

In addition, a higher mutation frequency of \textit{BRAF} V600E was observed in patients with higher TIADRS score and TBSRTC score. Some studies have shown the rates of malignancy in TBSRTC category I, III, and V nodules were 15.3%, 39.3%, and 96.8%, respectively, and \textit{BRAF} V600E exhibited similar diagnostic performance to that of TIRADS in BSRTC III/V nodules, the combination of the two diagnostic approaches significantly enhanced the sensitivity, especially among high TBSRTC higher TIADRS score and a TBSRTC score. Some studies have shown the rates of malignancy in patients with higher TIADRS score and TBSRTC score.

The \textit{BRAF} V600E mutation status was shown to be positive in 90.9% (10/11) patients with capsule invasion using FNA washout precipitation specimens, which was higher than that detected in patients without capsule invasion using FNA washout precipitation specimens 44.4% (12/27). As previous studies have shown that \textit{BRAF} alterations were significantly more common in PTCs with thyroid capsule invasion than in tumors that without thyroid capsule invasion. Giovanni have proposed that Large subcapsular mPTCs (group A: tumors size ≥5 mm and distance from the thyroid capsule = 0 mm) represent the group with the most worrisome characteristics, including aggressive growth with distinctively invasive features, such as infiltrative tumor border, intraglandular tumor spread, presence of psammoma bodies into the surrounding parenchyma, vascular invasion, and lymph node metastases. So, tumor cells were more readily available in the patients with capsule invasion. On the other hand, for the patients without capsule invasion, FNAB specimens tend to have a higher proportion of normal cells.

The results showed that FNA washout precipitation was a feasible specimen for \textit{BRAF} V600E mutation detection. In addition, the \textit{BRAF} V600E mutation was detected in thyroid FNA washout precipitation specimens, providing rapid genetic testing results for improving the accuracy of cytopathological diagnosis. Thus, the FNA washout precipitation specimen was an important supplement for the genetic detection of thyroid nodules. Among these 77 patients diagnosed as TBSRTC V and TBSRTC VI by cytopathology, I was found to be false negative using an FNA biopsy FFPE specimen, indicating that the FNA washout precipitation specimen, combined with the FNA biopsy FFPE specimen, could be used as an effective supplementary specimen to reduce the false-negative rate of \textit{BRAF} gene detection in thyroid cancer.

This study had several limitations. First, the proportion of tumor cells in fresh FNA thyroid tissue samples was unknown. Fresh samples might have no or insufficient tumor cells, which did not reach the detection limit of the genetic test kit. Second, the number of patients included in the study was not sufficient. Third, only cytology FFPE samples were used for comparison due to the lack of tissue sample validation (histopathological results of 82 patients were obtained). Fourth, fewer genes were detected. Thus, further large-scale and multigene prospective investigations are warranted to solve some of these limitations.

### Conclusion

115 samples were successfully tested using both FNA washout precipitation and biopsy FFPE specimens in this study. The results indicated that FNA washout precipitation specimens could be used as a supplementary sample type to shorten the genetic testing cycle on the basis of ensuring PPV. Furthermore, \textit{BRAF} V600E mutations in FNA washout precipitation specimens showed 100.0% sensitivity and 100.0% specificity for diagnosing patients with PTC having thyroid capsule invasion.

### Acknowledgments

We are extremely grateful to Dr Fei Yao and Yanfang Chen, Medical Research Department of Amoy Diagnostics Co., Ltd, for their support in this study.

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Author Contributions

Dan He, Yueting Liao, Yongmei Cui, and Xiangqi Huang design the conception; Yongmei Cui, Xiangqi Huang collect and assemble data;

---

**Table 4. Relationship between clinical characteristics and \textit{BRAF} V600E mutation in PTC**

| Characteristics | \textit{BRAF}(V600E) Mut | \textit{BRAF}(V600E) WT | \textit{P} value |
|-----------------|------------------------|----------------------|----------------|
| Sex             |                        |                      | 0.513          |
| Male            | 12 (66.7%)             | 6 (33.3%)            |                |
| Female          | 47 (77.1%)             | 14 (22.9%)           |                |
| Age (year)      |                        |                      | 0.208          |
| ≤45             | 43 (71.7%)             | 17 (28.3%)           |                |
| >45             | 16 (84.2%)             | 3 (15.8%)            |                |
| Lesions         |                        |                      | 0.930          |
| Single lesion   | 15 (75.0%)             | 5 (25.0%)            |                |
| Multifocality   | 38 (76.0%)             | 12 (24.0%)           |                |
| Tumor size      |                        |                      | 0.030          |
| ≤10 mm          | 17 (63.0%)             | 10 (37.0%)           |                |
| >10 mm          | 32 (88.9%)             | 4 (11.1%)            |                |
| Capsule invasion|                        |                      | 0.999          |
| No              | 10 (90.9%)             | 1 (9.1%)             |                |
| Lymph metastasis|                        |                      | 0.999          |
| Yes             | 21 (84.0%)             | 4 (16.0%)            |                |
| No              | 6 (85.7%)              | 1 (14.3%)            |                |

Mut: Mutation; WT: Wild Type.
Jinrui Guo, Nana Zhang and Jing Liang collect samples; and Nana Zhang, Yiwan Zhang are responsible for the cytopathological and histopathological diagnosis. Nana Zhang, Yongmei Cui, and Yueting Liao are the guarantors of this work. Yueting Liao and Dan He, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the National Natural Science Foundation of China (81702409, 81902416), and the National Natural Science Youth Cultivation Foundation of The Third Affiliated Hospital of Sun Yat-sen University, and Foundation of Xiamen Municipal Bureau of Science and Technology (China, IDs: 3502Z20184038).

Ethical Statement
This observational clinical study was approved by the institutional review board by the Third Affiliated Hospital of Sun Yat-sen University Ethics Committee with exemption of informed consent (approve number: [2020] 02-289-01), and all participants provided informed verbal consent.

ORCID iD
Dan He https://orcid.org/0000-0002-6731-283X

Supplemental Material
Supplemental material for this article is available online.

References
1. Wong R, Farrell SG. Grossmann M: thyroid nodules: diagnosis and management. Med J Aust. 2018;209(2):92-98.
2. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ. Cooper DS: the diagnosis and management of thyroid nodules: a review. Jama. 2018;319(9):914-924.
3. Kant R, Davis A, Verma V. Thyroid nodules: advances in evaluation and management. Am Fam Physician. 2020:102(5):298-304.
4. Rossi ED, Pantanowitz L. Faquin WC: the role of molecular testing for the indeterminate thyroid FNA. Genes (Basel). 2019;10(10):736.
5. Jung CK, Hong S, Bychkov A, Kakudo K. The Use of fine-needle aspiration (FNA) cytology in patients with thyroid nodules in Asia: a brief overview of studies from the working group of Asian thyroid FNA cytology. J Pathol Transl Med. 2017;51(6):571-578.
6. Moon HJ, Son E, Kim EK, Yoon JH. Kwak JY: the diagnostic values of ultrasound and ultrasound-guided fine needle aspiration in subcentimeter-sized thyroid nodules. Ann Surg Oncol. 2012;19(1):52-59.
7. Satturwar SP, Rossi ED. Thyroid paraganglioma: a diagnostic pitfall in thyroid FNA. Cancer Cytopathol. 2021;129(6):439-449.
8. Poller DN. Glayscher S: molecular pathology and thyroid FNA. Cytopathology : official journal of the British Society for Clinical Cytopathology. 2017;28(6):475-481.
9. Koh J, Choi JR, Han KH, Kim EK, Yoon JH, Moon HJ. Kwak JY: proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules. PloS one. 2013;8(5):e64505.
10. Danilovic DL, Lima EU, Domingues RB, Brandão LG, Hoff AO. Marui S: pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol. 2014;170(4):619-625.
11. Gómez Sáez JM. Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics. 2011;12(8):597-608.
12. Kaya C, Dorsaint P, Mercurio S, et al. Limitations of detecting genetic variants from the RNA sequencing data in tissue and fine-needle aspiration samples. Thyroid : official journal of the American Thyroid Association. 2021;31(4):589-595.
13. Zhu XH, Zhou JN, Qian YY, et al. Diagnostic values of thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis diagnostic values of FNA-Tg. Endocr J. 2020;67(2):113-123.
14. Trimboli P, D’Aurizio F, Tozzoli R, Giovanella L. Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. Clin Chem Lab Med. 2017;55(7):914-925.
15. Zhu Y, Song Y, Xu G, Fan Z, Ren W. The Bethesda system for reporting thyroid cytopathology (TBSRTC): a report of 2,781 cases in a Chinese population. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2020;32(2):140-148.
16. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid : official journal of the American Thyroid Association. 2017;27(11):1341-1346.
17. Lu ZZ, Zhang Y, Wei SF, et al. Outcome of papillary thyroid microcarcinoma: study of 1,990 cases. Mol Clin Oncol. 2015;3(3):672-676.
18. Zhang YZ, Xu T, Cui D, et al. Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules. Sci Rep. 2015;5:16927.
19. Li X, Li E, Du J, Wang J. Zheng B: BRAF mutation analysis by ARMS-PCR refines thyroid nodule management. Clin Endocrinol (Oxf). 2019;91(6):834-841.
20. Xing M, Tufano RP, Tufaro AP, et al. Ladenson PW: detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 2004;89(6):2867-2872.
21. Cohen Y, Rosenbaum E, Clark DP, et al. Westra WH: mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Sci Rep. 2021;10(8):2761-2765.
22. Brigante G, Craparo A, Pignatti E, Marino M, Monzani ML. Real-life use of BRAF-V600E mutation analysis in thyroid nodule fine needle aspiration: consequences on clinical decision-making. 2021;73(3):625-632.
23. Wu Y, Xu T, Cao X, et al. BRAF (V600e) versus TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules. Cancer Biol Med. 2019;16(1):131-138.
24. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95(9):4197-4205.
25. Tallini G, De Leo A, Repaci A, et al. Does the site of origin of the microcarcinoma with respect to the thyroid surface matter? A multicenter pathologic and clinical study for risk stratification. Cancers (Basel). 2020;12(1).